ArticleBMJ open diabetes research & care2020
Metformin and statin use associate with plasma protein
Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Large glycomics datasets as a tool to understand the function of glycans.Nature chemical biology · 2026Review
- Glycosylation as a strategic mechanism for measles virus and mumps virus immune evasion.Frontiers in immunology · 2025Review
- N-glycan as new potential biomarker for predicting treatment response in patients with type 2 diabetes mellitus.Biomarkers in medicine · 2024Article
- Protein posttranslational modifications in metabolic diseases: basic concepts and targeted therapies.MedComm · 2024Review
- Clinical glycoproteomics: methods and diseases.MedComm · 2024Review
- The Human BloodJACS Au · 2024Review
- Metformin mitigates radiation toxicity exerting antioxidant and genoprotective properties.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- High-Throughput Glycomic Methods.Chemical reviews · 2022Review
- Multi-block data integration analysis for identifying and validating targeted N-glycans as biomarkers for type II diabetes mellitus.Scientific reports · 2022Article
- N-glycan Characterization by Liquid Chromatography Coupled with Fluorimetry and Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Plasma proteinBMJ open diabetes research & care · 2021Article
- Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecent studies revealed RESEARCH DESIGN AND
methodsAfter enzymatic release from glycoproteins,
resultsMetformin and statins were associated with decreased fucosylation and increased galactosylation and sialylation in glycans unrelated to immunoglobulin G. Bisection was increased within diantennary fucosylated non-sialylated glycans, but decreased within diantennary fucosylated sialylated glycans. Only few glycans were associated with ACE inhibitor/ARBs, while none associated with insulin and SU derivative use.
conclusionsWe conclude that metformin and statins associate with a total plasma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.